Xencor
Clinical-stage biotechnology company focused on structure-guided engineering of antibody Fc domains to create bispecific and monospecific antibody therapeutics with modified immune functions (e.g., tuned effector activity, extended half-life, reduced immunogenicity). Operates an internal and partnered development pipeline across oncology and autoimmune indications and conducts preclinical, translational and clinical development through Phase 2/3.
Industries
Nr. of Employees
large (251-1000)
Patents
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US-12662553-B2
View DetailsHeterodimeric human IgG1 polypeptides with isoelectric point modifications
US-12617872-B2
View DetailsLAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and LAG-3 antigen binding domains
US-12509495-B2
View Details
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US-12662553-B2
View DetailsHeterodimeric human IgG1 polypeptides with isoelectric point modifications
US-12617872-B2
View DetailsLAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and LAG-3 antigen binding domains
US-12509495-B2
View DetailsProducts
XmAb819 (ENPP3 x CD3)
2+1 bispecific T-cell engager in Phase 1 for clear cell renal cell carcinoma and ENPP3+ tumors; IV and SC dose-escalation with expansion cohorts planned to support pivotal study.
XmAb541 (CLDN6 x CD3)
2+1 bispecific T-cell engager engineered for CLDN6 selectivity in Phase 1 dose-escalation for CLDN6+ ovarian, endometrial and germ cell tumors; companion IHC prescreening used for enrollment.
XmAb808 (B7-H3 x CD28)
2+1 bispecific designed to provide tumor-conditional CD28 co-stimulation to potentiate T-cell activation; evaluated in combination with tumor-targeting bispecifics in Phase 1.
XmAb942 (anti-TL1A, Xtend Fc)
Monospecific anti-TL1A antibody using half-life extension Fc and Fc-silencing technologies; Phase 1 completed in healthy volunteers and Phase 2b (XENITH-UC) ongoing for ulcerative colitis.
XmAb412 (TL1A x IL23p19, XenLock bispecific)
Paired bispecific engineered for dual inhibition in IBD with an IgG-format intended for subcutaneous delivery; first-in-human dosing planned.
Plamotamab (CD20 x CD3)
CD20 x CD3 bispecific under development for autoimmune indications; Phase 1b proof-of-concept study in rheumatoid arthritis described.
XmAb819 (ENPP3 x CD3)
2+1 bispecific T-cell engager in Phase 1 for clear cell renal cell carcinoma and ENPP3+ tumors; IV and SC dose-escalation with expansion cohorts planned to support pivotal study.
XmAb541 (CLDN6 x CD3)
2+1 bispecific T-cell engager engineered for CLDN6 selectivity in Phase 1 dose-escalation for CLDN6+ ovarian, endometrial and germ cell tumors; companion IHC prescreening used for enrollment.
XmAb808 (B7-H3 x CD28)
2+1 bispecific designed to provide tumor-conditional CD28 co-stimulation to potentiate T-cell activation; evaluated in combination with tumor-targeting bispecifics in Phase 1.
XmAb942 (anti-TL1A, Xtend Fc)
Monospecific anti-TL1A antibody using half-life extension Fc and Fc-silencing technologies; Phase 1 completed in healthy volunteers and Phase 2b (XENITH-UC) ongoing for ulcerative colitis.
XmAb412 (TL1A x IL23p19, XenLock bispecific)
Paired bispecific engineered for dual inhibition in IBD with an IgG-format intended for subcutaneous delivery; first-in-human dosing planned.
Plamotamab (CD20 x CD3)
CD20 x CD3 bispecific under development for autoimmune indications; Phase 1b proof-of-concept study in rheumatoid arthritis described.
Expertise Areas
- Antibody Fc-domain engineering
- Bispecific antibody design and development
- Clinical trial management (Phase 1–3)
- Translational pharmacology and PK/PD/QSP modeling
Key Technologies
- Structure-based protein design
- Fc-domain engineering
- Bispecific antibody formats (2+1 and heterodimeric Fc scaffolds)
- FcRn affinity modulation for half-life extension
News & Updates
Aggregated peer-reviewed papers and conference posters describing Fc-domain technologies, bispecific and monospecific program preclinical and clinical findings across XmAb programs (includes references for bispecific Fc domain design, cytotoxic Fc variants, immune inhibitor Fc variants and Xtend half-life extension).
Presentation summarizing Phase 1 healthy volunteer results for an anti-TL1A antibody (XmAb942), preclinical characterization of a TL1A x IL23p19 bispecific, and clinical strategy updates.
Initial dose-escalation results for an ENPP3 x CD3 T-cell engager in advanced clear cell renal cell carcinoma including safety, pharmacokinetics and early efficacy.
Reported global patent portfolio covering engineered Fc-domain technologies and related platforms (described as more than 1,500 patents worldwide).
Initial clinical data including safety, PK supporting weekly-to-q2w dosing, and preliminary efficacy in heavily pre-treated ccRCC patients; supported selection of dose-expansion cohorts and planning for pivotal study.
Final Phase 1 results showing safety, extended half-life and favorable immunogenicity profile to support Phase 2b XENITH-UC study.
Aggregated peer-reviewed papers and conference posters describing Fc-domain technologies, bispecific and monospecific program preclinical and clinical findings across XmAb programs (includes references for bispecific Fc domain design, cytotoxic Fc variants, immune inhibitor Fc variants and Xtend half-life extension).
Presentation summarizing Phase 1 healthy volunteer results for an anti-TL1A antibody (XmAb942), preclinical characterization of a TL1A x IL23p19 bispecific, and clinical strategy updates.
Initial dose-escalation results for an ENPP3 x CD3 T-cell engager in advanced clear cell renal cell carcinoma including safety, pharmacokinetics and early efficacy.
Reported global patent portfolio covering engineered Fc-domain technologies and related platforms (described as more than 1,500 patents worldwide).
Initial clinical data including safety, PK supporting weekly-to-q2w dosing, and preliminary efficacy in heavily pre-treated ccRCC patients; supported selection of dose-expansion cohorts and planning for pivotal study.
Final Phase 1 results showing safety, extended half-life and favorable immunogenicity profile to support Phase 2b XENITH-UC study.